Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease

被引：1
|
作者：
Kesten, Steven [1 ]
Leimer, Inge [1 ]
Jara, Michele [2 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] Epidemiol Consulting, Danbury, CT USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2009年 / 301卷 / 12期
关键词：
TIOTROPIUM; TRIAL; COPD;
D O I：
10.1001/jama.2008.947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1224 / 1224
页数：1
相关论文
共 50 条
  • [1] Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease In Reply
    Singh, Sonal
    Loke, Yoon K.
    Furberg, Curt D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (12): : 1225 - 1226
  • [2] Review: Inhaled anticholinergics increase risk for major cardiovascular events in chronic obstructive pulmonary disease
    Stanbrook, Matthew B.
    ANNALS OF INTERNAL MEDICINE, 2009, 150 (02)
  • [3] Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease - A systematic review and meta-analysis
    Singh, Sonal
    Loke, Yoon K.
    Furberg, Curt D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (12): : 1439 - 1450
  • [4] Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis (vol 300, pg 1439, 2008)
    Singh, S.
    Loke, Y. K.
    Furberg, C. D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (12): : 1227 - 1230
  • [5] Inhaled Anticholinergics for Chronic Obstructive Pulmonary Disease
    Singh, Sonal
    Furberg, Curt D.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (10) : 920 - 922
  • [6] Inhaled anticholinergics: increased risk of major adverse CV events?
    Reactions Weekly, 2008, 1222 (1) : 3 - 3
  • [7] Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease
    Rogliani, Paola
    Calzetta, Luigino
    Matera, Maria Gabriella
    di Daniele, Nicola
    Girolami, Andrea
    Cazzola, Mario
    Ora, Josuel
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (06) : 737 - 750
  • [8] The use of inhaled anticholinergics in chronic obstructive pulmonary disease Is there cause for concern of cardiovascular safety?
    McIvor, R. Andrew
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (11): : 697 - 698
  • [9] Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
    Wang, Meng-Ting
    Lai, Jyun-Heng
    Tsai, Chen-Liang
    Liou, Jun-Ting
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2019, 27 (03) : 657 - 670
  • [10] Major Adverse Cardiovascular Events In Patients With Chronic Obstructive Pulmonary Disease: Analysis Of 14 Pooled Roflumilast Studies
    White, W. B.
    Gorelick, P. B.
    Cooke, G.
    Rabe, K. F.
    Calverley, P. M.
    Fabbri, L. M.
    Martinez, F. J.
    Bredenbroeker, D.
    Mosberg, H.
    Palm, U.
    Lakkis, H.
    Zhu, H.
    Jain, V.
    Boykin, D.
    Rowe, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
12345